Stock EBS EMERGENT BIOSOLUTIONS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Emergent BioSolutions Inc.

Equities

EBS

US29089Q1058

Market Closed - Nyse
Other stock markets
 04:00:02 2024-06-06 pm EDT 		5-day change 1st Jan Change
6.26 USD -6.15% Intraday chart for Emergent BioSolutions Inc. +22.99% +160.83%
May. 02 Sector Update: Health Care Stocks Softer Late Afternoon MT
May. 02 Sector Update: Health Care MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The stock, which is currently worth 2024 to 0.45 times its sales, is clearly overvalued in comparison with peers.
  • The company appears to be poorly valued given its net asset value.
  • The company has a low valuation given the cash flows generated by its activity.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analyst opinion has improved significantly over the past four months.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The company is in debt and has limited leeway for investment
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
EMERGENT BIOSOLUTIONS INC. Stock Emergent BioSolutions Inc.
+160.83% 350M
C
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+43.64% 749B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.42% 605B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.58% 351B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.72% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.78% 292B
C+
NOVARTIS AG Stock Novartis AG
+11.92% 216B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-2.62% 214B
A+
PFIZER, INC. Stock Pfizer, Inc.
+0.03% 167B
C+
AMGEN INC. Stock Amgen Inc.
+6.13% 165B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. EBS Stock
  4. Ratings Emergent BioSolutions Inc.